Abstract
Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18- fluorodeoxyglucose (18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.
Keywords: CT, PET, RECISTcriteria, RECIST 1.1 criteria, solid tumors, targeted-therapies, computed tomography (CT), positron emission tomography (PET), Response Evaluation Criteria in Solid Tumors (RECIST), Gastro Intestinal Solid Tumors (GIST), Hepatocellular Carcinoma, 18-fluorodeoxyglucose (18FDG, nonsmall lung cancer, colorectal cancer, molecularly targeted drugs
Reviews on Recent Clinical Trials
Title: Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Volume: 6 Issue: 3
Author(s): Amalia Milano, Francesco Perri, Andrea Ciarmiello and Francesco Caponigro
Affiliation:
Keywords: CT, PET, RECISTcriteria, RECIST 1.1 criteria, solid tumors, targeted-therapies, computed tomography (CT), positron emission tomography (PET), Response Evaluation Criteria in Solid Tumors (RECIST), Gastro Intestinal Solid Tumors (GIST), Hepatocellular Carcinoma, 18-fluorodeoxyglucose (18FDG, nonsmall lung cancer, colorectal cancer, molecularly targeted drugs
Abstract: Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18- fluorodeoxyglucose (18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.
Export Options
About this article
Cite this article as:
Milano Amalia, Perri Francesco, Ciarmiello Andrea and Caponigro Francesco, Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?, Reviews on Recent Clinical Trials 2011; 6 (3) . https://dx.doi.org/10.2174/157488711796575540
DOI https://dx.doi.org/10.2174/157488711796575540 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form
Current Pharmaceutical Analysis Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
Medicinal Chemistry Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Epigenomics
Current Drug Metabolism Recent Technological Advances in the Mass Spectrometry-based Nanomedicine Studies: An Insight from Nanoproteomics
Current Pharmaceutical Design Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Molecular Pathways, Screening and Follow-up of Colorectal Carcinogenesis: An Overview
Current Cancer Therapy Reviews The Role of Dietary Approach in Irritable Bowel Syndrome
Current Medicinal Chemistry The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients
Inflammation & Allergy - Drug Targets (Discontinued) Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging